$27.47
-0.43-1.54%
At Close: -
$27.47
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Anika Therapeutics (NASDAQ:ANIK) Stock, Analyst Ratings, Price Targets, Forecasts
Anika Therapeutics Inc has a consensus price target of $30.5 based on the ratings of 3 analysts. The high is $37 issued by Barrington Research on May 9, 2024. The low is $24 issued by Stephens & Co. on May 29, 2024. The 3 most-recent analyst ratings were released by Stephens & Co., Barrington Research, and Stephens & Co. on May 29, 2024, May 9, 2024, and March 14, 2024, respectively. With an average price target of $27.67 between Stephens & Co., Barrington Research, and Stephens & Co., there's an implied 0.72% upside for Anika Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
Barrington Research
1calculated from analyst ratings
Analyst Ratings for Anika Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/29/2024 | Buy Now | -12.63% | Stephens & Co. | George Sellers | $24 → $24 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 34.69% | Barrington Research | Michael Petusky | $37 → $37 | Maintains | Outperform | Get Alert |
| 03/14/2024 | Buy Now | -19.91% | Stephens & Co. | George Sellers | → $22 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 03/14/2024 | Buy Now | 34.69% | Barrington Research | Michael Petusky | $29 → $37 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | 5.57% | Barrington Research | Michael Petusky | $28 → $29 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 1.93% | Barrington Research | Michael Petusky | $24 → $28 | Maintains | Outperform | Get Alert |
| 08/14/2023 | Buy Now | -12.63% | Barrington Research | Michael Petusky | → $24 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | -16.27% | Stephens & Co. | George Sellers | $28 → $23 | Maintains | Equal-Weight | Get Alert |
| 05/31/2023 | Buy Now | 1.93% | Stephens & Co. | George Sellers | → $28 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/14/2023 | Buy Now | 1.93% | Stephens & Co. | George Sellers | → $28 | Reiterates | → Equal-Weight | Get Alert |
| 03/07/2023 | Buy Now | — | Barrington Research | Michael Petusky | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/09/2022 | Buy Now | 12.85% | Barrington Research | Michael Petusky | → $31 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/14/2022 | Buy Now | -5.35% | Stephens & Co. | George Sellers | → $26 | Reinstates | → Equal-Weight | Get Alert |
| 03/09/2022 | Buy Now | — | Stephens & Co. | Chris Cooley | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/16/2021 | Buy Now | 100.22% | Stephens & Co. | Chris Cooley | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Anika Therapeutics (ANIK) stock?
The latest price target for Anika Therapeutics (NASDAQ:ANIK) was reported by Stephens & Co. on May 29, 2024. The analyst firm set a price target for $24.00 expecting ANIK to fall to within 12 months (a possible -12.63% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anika Therapeutics (ANIK)?
The latest analyst rating for Anika Therapeutics (NASDAQ:ANIK) was provided by Stephens & Co., and Anika Therapeutics reiterated their equal-weight rating.
When was the last upgrade for Anika Therapeutics (ANIK)?
The last upgrade for Anika Therapeutics Inc happened on August 14, 2023 when Barrington Research raised their price target to $24. Barrington Research previously had a market perform for Anika Therapeutics Inc.
When was the last downgrade for Anika Therapeutics (ANIK)?
The last downgrade for Anika Therapeutics Inc happened on March 7, 2023 when Barrington Research changed their price target from N/A to N/A for Anika Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Anika Therapeutics (ANIK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on May 29, 2024 so you should expect the next rating to be made available sometime around May 29, 2025.
Is the Analyst Rating Anika Therapeutics (ANIK) correct?
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a reiterated with a price target of $24.00 to $24.00. The current price Anika Therapeutics (ANIK) is trading at is $27.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.